By Stanley Widianto and Roxanne Liu
JAKARTA/BEIJING (Reuters) – Indonesia said it has granted emergency use approval to an mRNA COVID-19 vaccine developed by a Chinese company, becoming the first country, ahead of even China, to do so.
Indonesia’s food and drugs agency (BPOM) greenlighted the use of Walvax Biotechnology Co Ltd’s mRNA vaccine, which has been in development for more than two years and targets the original strain of the coronavirus.
The approval comes as somewhat of a surprise as Walvax, which has been conducting large late-stage trials of the vaccine in several countries including Indonesia, Mexico and China, has yet to publish efficacy readings that would show how well it can reduce the risk of COVID cases and deaths.
Penny Lukito, head of the agency, told reporters the vaccine, now known as AWcorna, was 83.58% effective against wild-type coronavirus strains considered common and normal, though she added that its efficacy drops to 71.17% against moderate cases of the highly contagious Omicron variant.
She did not provide details of the data and did not respond to Reuters queries seeking further comment.
Walvax declined to comment. Share reaction for the Chinese company was muted, with the stock rising just 0.5%.
Indonesia has previously granted emergency use approvals to other Chinese COVID shots before detailed efficacy data became available, though that was earlier on in the pandemic when Western-made products were in short supply.
China has several mRNA candidates in development but the Walvax vaccine is the only candidate in large late-stage clinical trials.
It was not immediately clear how widely the newly approved shot will be used in Indonesia, where more than 63% of its population is fully vaccinated. Health experts around the world also recommend using so-called bivalent COVID vaccines, which target both the original strain and the Omicron variant.
Indonesia also uses mRNA COVID vaccines made by Pfizer Ltd and BioNTech SE and by Moderna, but the AWcorna shot has a longer shelf life, remaining stable at 2 to 8 degrees Celsius (36 degrees to 46 degrees Fahrenheit) for at least six months, according to its researchers.
That could make the vaccine ideal for Indonesia, an archipelago of thousands of islands, and other countries which have poor logistics in remote areas.
BPOM said the vaccine’s less stringent storage requirements suited Indonesia, a tropical country, and it could be used as both a primary and a booster shot for adults.
The vaccine will be locally produced by an Indonesian firm, Etana Biotechnologies.
Etana declined to say how many doses of AWcorna it plans to produce, but said its production capacity is 100 million doses per year, spokesperson Lusy Andriani told Reuters.
Dicky Budiman, an Indonesian epidemiologist at Australia’s Griffith University, said producing AWcorna at home via technology transfer would help the country develop sufficient expertise as it seeks to prepare for new variants and possible shortages of vaccines.
“It’s important and strategic,” he said.
Walvax co-developed the vaccine with Suzhou Abogen Biosciences Co Ltd and a Chinese military-backed institution.
Walvax and Suzhou Abogen are also separately working on their own mRNA candidates that target coronavirus variants.
For its part, China has not approved any Western-made COVID shots and its approved vaccine portfolio does not yet include vaccines that specifically target the Omicron variant.
(Reporting by Stanley Widianto in Jakarta and Roxanne Liu in Beijing; Editing by Miyoung Kim, Edwina Gibbs and Jonathan Oatis)